Eledon Pharmaceuticals - ELDN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 697.10 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.76
+0 (0.00%)

This chart shows the closing price for ELDN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eledon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ELDN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ELDN

Analyst Price Target is $22.00
▲ +697.10% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Eledon Pharmaceuticals in the last 3 months. The average price target is $22.00, with a high forecast of $26.00 and a low forecast of $15.00. The average price target represents a 697.10% upside from the last price of $2.76.

This chart shows the closing price for ELDN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Eledon Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/4/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/2/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/29/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/2/2022HC WainwrightReiterated RatingBuy$25.00Low
6/1/2022SVB LeerinkLower TargetOutperform$33.00 ➝ $26.00High
5/13/2022Cantor FitzgeraldInitiated CoverageOverweight$25.00 ➝ $15.00Low
3/29/2022Cantor FitzgeraldReiterated RatingOverweightLow
3/25/2022Lifesci CapitalReiterated RatingOutperformMedium
1/14/2022HC WainwrightReiterated RatingBuy$25.00Low
11/24/2021HC WainwrightLower TargetBuy$35.00 ➝ $25.00Low
11/14/2021SVB LeerinkReiterated RatingBuy$33.00Medium
4/27/2021SVB LeerinkLower TargetOutperform$34.00 ➝ $33.00High
3/29/2021SVB LeerinkReiterated RatingBuy$34.00Low
3/22/2021Cantor FitzgeraldInitiated CoverageOverweight$25.00Medium
3/18/2021Lifesci CapitalReiterated RatingOutperformHigh
2/8/2021SVB LeerinkInitiated CoverageOutperform$34.00Low
(Data available from 9/29/2017 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/3/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/2/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/2/2022
  • 4 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/1/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/1/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/30/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2022

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Eledon Pharmaceuticals logo
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Read More

Today's Range

Now: $2.76
Low: $2.70
High: $2.87

50 Day Range

MA: $3.28
Low: $2.70
High: $3.88

52 Week Range

Now: $2.76
Low: $2.27
High: $6.50

Volume

26,600 shs

Average Volume

56,666 shs

Market Capitalization

$37.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Eledon Pharmaceuticals?

The following Wall Street analysts have issued reports on Eledon Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, Lifesci Capital, and SVB Leerink LLC.
View the latest analyst ratings for ELDN.

What is the current price target for Eledon Pharmaceuticals?

3 Wall Street analysts have set twelve-month price targets for Eledon Pharmaceuticals in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 697.1%. SVB Leerink LLC has the highest price target set, predicting ELDN will reach $26.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $15.00 for Eledon Pharmaceuticals in the next year.
View the latest price targets for ELDN.

What is the current consensus analyst rating for Eledon Pharmaceuticals?

Eledon Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ELDN will outperform the market and that investors should add to their positions of Eledon Pharmaceuticals.
View the latest ratings for ELDN.

What other companies compete with Eledon Pharmaceuticals?

How do I contact Eledon Pharmaceuticals' investor relations team?

Eledon Pharmaceuticals' physical mailing address is 19900 MACARTHUR BOULEVARD SUITE 550, IRVINE CA, 92612. The company's listed phone number is (949) 238-8090 and its investor relations email address is [email protected] The official website for Eledon Pharmaceuticals is novustherapeutics.com. Learn More about contacing Eledon Pharmaceuticals investor relations.